On November 5, at its Innovation Center near Munich, the pharmaceutical company Roche awarded three prizes in the field of oncology research, recognizing Albin Jeanne for his work on a new anti-tumor peptide drug. This new approach inhibits the development of blood vessels in extracellular matrix tumors. The jury recognized that he had thus discovered a new biological application in an essential field of research on anti-angiogenesis.
Albin Jeanne was recruited by SATT Nord as part of the CD47 project led by the University of Reims Champagne-Ardenne, supported and funded by SATT Nord. This project focuses on an antagonist peptide drug with anti-tumor and anti-metastatic properties. It offers the prospect of improving the effectiveness of chemotherapy treatments and reducing the associated side effects.
More information about the CD47 project:About the award
The pRED Discovery Oncology Prize was created three years ago by the Oncology Discovery unit at Roche's Innovation Center in Penzberg. Applications are open to European researchers. By organizing this award ceremony, Roche aims to intensify its exchanges with the international oncology research community. The jury is composed of six renowned experts and researchers (three European professors and three representatives from Roche's Oncology department).